Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (34895532) | ||||||||||||
| Authors | Andrews JP, Coleman C, Hastings C, Sun PP | ||||||||||||
| Title | Oncogenic NTRK fusion in congenital spinal cord glioblastoma: sequencing directs treatment. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion | glioblastoma | predicted - sensitive | Carboplatin + Etoposide + Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (larotrectinib), Paraplatin (carboplatin), and Vepesid (etoposide) combination treatment resulted in complete tumor regression after 8 weeks in a pediatric patient with congenital spinal cord glioblastoma harboring an NTRK1 fusion, who remained tumor-free at 17 months (PMID: 34895532). | 34895532 |